In his ceres Lecture, von Bohlen und Halbach discussed potential benefits and challenges of Big Data for modern medicine. The constantly growing amount of health-related data is changing health care practice fundamentally. While medicine is expected to be personalized and to allow for increasingly precise predictions as well as individualized therapies, it is not settled whether Precision Medicine will automatically lead to better patient care. Which risks are associated with data-driven care, and how can we ensure its beneficial use?
May 23rd, 2016
6.30 p.m. – 8.00 p.m.
University Hospital Cologne
Kerpener Str. 62
Dr. Friedrich von Bohlen und Halbach is managing partner and co-founder of
dievini Hopp BioTech Holding GmbH & Co. KG., the company managing the life science activities and investments of Dietmar Hopp, co founder of SAP, and his family.
Friedrich von Bohlen holds a diploma in biochemistry from the University of Zurich and a PhD in neurobiology from the Swiss Federal Institute of Technology (ETH) in Zurich. He held various positions at Fresenius AG, FAG Kugelfischer KGaA and WASAG Chemie AG.
In 1997 he founded LION bioscience AG (now Sygnis AG), whose CEO he was for seven years.
He is chairman of the Board of Apogenix AG, CureVac AG, Molecular Health GmbH and Novaliq GmbH, as well as board member of AC Immune SA, Cosmo Pharmaceuticals S.A., immatics biotechnologies GmbH, Sygnis AG, Wilex AG and member of the evaluation board of Wyss Translational Center Zurich.